A docket of the retatrutide trial record — regulatory questions first.

What Retatrutide Legal is

Retatrutide Legal keeps a docket on the peer-reviewed research literature covering retatrutide: each entry filed, dated, and traced back to the study it came from. No clinicians sit on it, and it dispenses no medical advice; it prescribes nothing, and it makes, stocks, and ships nothing. What it holds is a cited reading of published science.

The domain modifier "legal" is editorial positioning — it marks this site's focus on the regulatory and legal-status questions readers ask most about retatrutide (approval status, availability, compounding law, WADA status). It is not a claim that the site provides legal services, nor that it has verified any particular use of the compound to be lawful in any jurisdiction. The docket reports; it does not advise.

What we publish and why

Retatrutide is the most clinically active investigational obesity compound currently in late-stage trials — Phase 3 TRIUMPH data are beginning to emerge, and there is substantial public interest in understanding what the trial record actually says, as opposed to what gray-market vendors claim or what speculative coverage implies.

This site publishes plain-English summaries of the primary trial literature: Phase 1b pharmacokinetics, Phase 2 obesity and diabetes efficacy, Phase 2a MASLD findings, the first Phase 3 result (TRANSCEND-T2D-1), and the growing literature on what happens after stopping incretin-class therapy. Every quantitative claim cites a primary source. No claim is invented or extrapolated without citation.

The "legal status" angle — regulatory approval status, the gray-market landscape, the FDA's enforcement posture, the WADA question — is emphasized because it is the lens most readers of this domain bring. We apply the same citation standard to regulatory facts as to efficacy data.

What we are not

This is no telehealth platform, pharmacy, compounding pharmacy, clinic, or storefront. It processes no orders, issues no prescriptions, runs no consultations, and points no reader toward a supply channel. It endorses no gray-market product and states plainly the identity, purity, and sterility risks of non-trial retatrutide.

The docket is unaffiliated with Eli Lilly or any clinical-trial sponsor. Its contents are a reading of the published research — not promotional material, not funded by any pharmaceutical company, and not reviewed by the trial sponsor before publication.

Anyone seeking medical advice, treatment, or a prescription should speak with a licensed clinician. What this site keeps is a docket of the literature, nothing more.

Editorial standards

Every quantitative claim on this site is cited inline with a numbered reference that traces to a primary-source publication: a peer-reviewed journal article, a clinical trial registry entry, or an FDA document. We use generic compound names throughout — no trademark brand names appear in the site's editorial content. We distinguish between Phase 2 and Phase 3 data, between clinical findings and community anecdotes (the latter are labeled anecdotal, not clinical evidence where they appear), and between what is established and what remains genuinely open.

Accuracy corrections: if you identify a factual error, an incorrect citation, or a stale regulatory fact, the contact form is the appropriate channel.